USANA HEALTH SCIENCES INCUSNAEarnings & Financial Report
Usana Health Sciences, Inc., or USANA, is an American multi-level marketing company based in Salt Lake City, Utah. As of 2021, Usana was the 14th largest direct-selling company in the world by revenue. The company manufactures most of its nutritional products, dietary supplements, and skincare products at a Salt Lake City facility. Its products are sold in 24 countries via a network of independent distributors.
Revenue
$226.2M
Gross Profit
$176.8M
Operating Profit
$3.8M
Net Profit
N/A
Gross Margin
78.2%
Operating Margin
1.7%
Net Margin
N/A
YoY Growth
-10.0%
EPS
$-0.10
USANA HEALTH SCIENCES INC Q4 FY2026 Financial Summary
USANA HEALTH SCIENCES INC reported revenue of $226.2M (down 10.0% YoY) for Q4 FY2026, with a net profit of N/A (down 74.0% YoY) (N/A margin). Cost of goods sold was $49.4M, operating expenses totaled $173.0M.
Key Financial Metrics
| Total Revenue | $226.2M |
|---|---|
| Net Profit | N/A |
| Gross Margin | 78.2% |
| Operating Margin | 1.7% |
| Report Period | Q4 FY2026 |
USANA HEALTH SCIENCES INC Annual Revenue by Year
USANA HEALTH SCIENCES INC annual revenue history includes year-by-year totals (for example, 2025 revenue was $925.3M).
| Year | Annual Revenue |
|---|---|
| 2025 | $925.3M |
| 2024 | $854.5M |
| 2023 | $921.0M |
| 2022 | $998.6M |
| 2021 | $1.2B |
USANA HEALTH SCIENCES INC Quarterly Revenue & Net Profit History
USANA HEALTH SCIENCES INC results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2027 | $250.2M | -3.0% | $7.5M | 3.0% |
| Q4 FY2026 | $226.2M | -10.0% | N/A | N/A |
| Q4 FY2025 | $226.2M | -10.0% | $180.0K | 0.1% |
| Q3 FY2025 | $213.7M | +6.7% | $-6.5M | -3.1% |
| Q2 FY2025 | $235.8M | +10.8% | $9.7M | 4.1% |
| Q1 FY2025 | $249.5M | +9.5% | $9.4M | 3.8% |
| Q4 FY2024 | $213.6M | -3.4% | $4.5M | 2.1% |
| Q3 FY2024 | $200.2M | -6.2% | $10.6M | 5.3% |
Income Statement
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q4 2026 | Q1 2027 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $200.2M | $213.6M | $249.5M | $235.8M | $213.7M | $226.2M | $226.2M | $250.2M |
| YoY Growth | -6.2% | -3.4% | 9.5% | 10.8% | 6.7% | -10.0% | -10.0% | -3.0% |
Balance Sheet
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q4 2026 | Q1 2027 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $671.3M | $748.2M | $746.6M | $734.5M | $726.6M | $742.9M | $742.9M | $739.0M |
| Liabilities | $138.2M | $161.9M | $162.7M | $149.0M | $145.0M | $156.6M | $156.6M | N/A |
| Equity | $533.1M | $532.1M | $529.8M | $531.1M | $528.1M | N/A | N/A | N/A |
Cash Flow
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|
| Operating CF | $29.5M | $5.8M | $15.5M | $12.2M | $-2.0M |